MEHP, AhR, and Ovarian Follicle Toxicity

Environmental phthalates are widely studied endocrine-disrupting chemicals, but the molecular pathways connecting exposure to impaired ovarian function remain incompletely defined. In the reference article, Neff and colleagues examined whether the aryl hydrocarbon receptor is a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. The study was published in Biology of Reproduction in 2024 and is available through the reference study.

Study Background and Research Question

Di(2-ethylhexyl) phthalate, or DEHP, is used in many consumer, medical, and construction materials. Following exposure, DEHP is rapidly hydrolyzed to mono(2-ethylhexyl) phthalate, or MEHP, an active metabolite that can also be generated within the ovary. Previous work has associated MEHP with impaired follicle growth, altered steroidogenic gene expression, oxidative stress, follicle atresia, and abnormal hormone production. However, these observations did not establish which signaling pathway links MEHP exposure to ovarian dysfunction.

The authors focused on the aryl hydrocarbon receptor, AHR or AhR, a ligand-activated transcription factor that responds to environmental chemicals, endogenous molecules, and dietary compounds. After activation, AhR regulates xenobiotic-response genes including Cyp1a1 and Cyp1b1. These enzymes can alter estrogen metabolism, making AhR biologically relevant to both chemical defense and reproductive endocrinology. The central question was therefore whether AhR activation is required for, or contributes materially to, MEHP-mediated disruption of folliculogenesis and steroidogenesis in ovarian antral follicles.

Key Innovation from the Reference Study

The principal innovation was the use of pharmacological AhR antagonism to test mechanism rather than simply documenting that MEHP is toxic. The investigators compared follicles exposed to MEHP alone with follicles co-treated with the antagonist CH223191. Rescue of a toxic phenotype by pathway blockade provides stronger causal evidence than measuring AhR target genes alone.

The design also connected several biological levels in one experimental system: follicle growth as a tissue-level outcome, Cyp1a1 and Cyp1b1 as AhR-responsive transcripts, estrone and estradiol as functional endocrine outputs, and Pgr and Lhcgr as estrogen-sensitive signaling genes. This integrated structure is especially useful for reproductive toxicology because it links receptor activity to follicular development and hormone responsiveness. In this context, CH223191 functions as an aryl hydrocarbon receptor antagonist and an experimental AhR signaling pathway inhibitor, while the paper’s main contribution is the ovarian mechanism it helps reveal.

Methods and Experimental Design Insights

CD1 mouse ovarian antral follicles were isolated and maintained in culture. MEHP was applied across a concentration range, with or without CH223191, and the follicles were followed during a 96-hour exposure period. The investigators assessed follicle growth, measured steroid hormones released into the culture medium, and quantified expression of AhR target and estrogen-responsive genes. The published study should be consulted for the complete culture, measurement, and statistical procedures before attempting replication.

Protocol Parameters

• Biological model: Isolated CD1 mouse ovarian antral follicles were used to preserve interactions among follicular cell populations in an ex vivo system, as described in the reference study.
• MEHP exposure: The study tested MEHP from 0 to 400 μM. These are study-specific in vitro concentrations and should not be interpreted directly as human exposure levels.
• AhR antagonist treatment: CH223191 was included at 1 μM to evaluate whether blocking AhR could modify MEHP-associated responses.
• Exposure duration: Follicle growth was evaluated over 96 hours, allowing the investigators to observe both developmental and molecular responses during culture.
• Primary readouts: The workflow combined follicle growth, medium estrone and estradiol concentrations, Cyp1a1 and Cyp1b1 expression, and estrogen-sensitive Pgr and Lhcgr expression.

For experimental interpretation, the co-treatment arrangement is important. A decrease in toxicity after antagonist exposure is most informative when MEHP alone produces a reproducible phenotype and when the antagonist also suppresses the expected AhR transcriptional response. The authors’ inclusion of both receptor-linked molecular markers and endocrine outcomes strengthens that logic. Nevertheless, pharmacological rescue should be viewed as pathway-supporting evidence rather than a complete substitute for genetic AhR deletion or tissue-specific receptor manipulation.

Core Findings and Why They Matter

MEHP impaired follicle growth, with partial pharmacological rescue

MEHP exposure reduced the growth of mouse antral follicles during the culture period. Co-culture with CH223191 partially rescued this growth defect, indicating that AhR activity contributes to the developmental response. The rescue was incomplete, which is biologically informative: MEHP may activate additional stress, metabolic, or endocrine pathways alongside AhR, or the antagonist may not fully suppress receptor activity under the tested conditions.

This finding expands the interpretation of phthalate toxicity beyond generalized cellular injury. Follicle growth is an integrated process involving granulosa-cell proliferation, oocyte support, steroid production, and local signaling. A receptor-dependent reduction in growth suggests that environmental chemicals can interfere with several coordinated follicular functions through transcriptional signaling.

AhR target genes confirmed pathway engagement

MEHP increased expression of the established AhR-responsive genes Cyp1a1 and Cyp1b1. CH223191 blocked this induction, supporting the conclusion that MEHP activates AhR in the ovarian follicle model. This is a key mechanistic result because it establishes receptor engagement in ovarian tissue rather than assuming that AhR responses observed in liver, lung, or other cell types apply automatically to the ovary.

The result is also relevant to cytochrome P450 1A1 expression modulation. Because CYP1A1 and CYP1B1 participate in xenobiotic and estrogen metabolism, their induction could alter the local balance between active estrogens and less active metabolites. The study does not prove that altered CYP catalytic activity is the sole cause of the endocrine phenotype, but it provides a plausible molecular connection between MEHP exposure and disrupted ovarian estrogen signaling.

Estrogen production and signaling were disrupted

MEHP lowered estrone and estradiol concentrations in the culture medium relative to untreated controls. Co-treatment with CH223191 mitigated these reductions. MEHP also decreased expression of the estrogen-sensitive genes Pgr and Lhcgr, and antagonist treatment blocked this effect. Together, these results indicate that MEHP affects both estrogen availability and downstream estrogen-responsive signaling.

The findings therefore support a model in which MEHP activates AhR, alters receptor-responsive transcription, and contributes to reduced estrogen production and signaling in antral follicles. The data are particularly meaningful because the same antagonist intervention influenced growth, steroid output, and hormone-responsive transcripts. That convergence is more persuasive than a single endpoint, while the partial nature of some responses appropriately leaves room for AhR-independent mechanisms.

Why this cross-domain matters, maturity, and limitations

The study sits at the intersection of reproductive biology and environmental toxicology research. AhR is also associated with responses to dioxins and polycyclic aromatic hydrocarbons, so the work may inform a broader dioxin toxicity mechanism study by showing how AhR-linked transcription can intersect with ovarian steroidogenesis. However, the paper tested MEHP in mouse follicles, not TCDD or another dioxin in an in vivo reproductive model. It therefore supports a receptor-level conceptual bridge, not direct equivalence between phthalate and dioxin toxicity.

This distinction matters when selecting an AhR antagonist for dioxin toxicity research or interpreting results from a TCDD-induced toxicity model. Receptor ligand selectivity, tissue context, exposure timing, metabolism, and downstream transcriptional programs can differ substantially. The ovarian findings are mechanistically suggestive and experimentally mature for an ex vivo mouse follicle system, but they should not be generalized to human fertility risk or other toxicants without additional validation.

Comparison with Existing Internal Articles (if available)

The internal article CH 223191: Applied Workflows for Aryl Hydrocarbon Receptor Antagonism emphasizes practical antagonist workflows, troubleshooting, and experimental implementation. Its scope is broader than the reference study, whereas the Neff et al. paper provides primary evidence from a defined ovarian follicle model and identifies specific growth, hormone, and transcript responses.

A second resource, CH 223191 in Environmental Toxicology: Decoding AhR Antagonism, frames AhR antagonism across environmental toxicology applications. The present paper adds a reproductive-tissue example to that broader context. These internal articles can help organize experimental planning, but they should be used alongside the original publication for dose interpretation, endpoint selection, and biological conclusions.

Limitations and Transferability

The ex vivo mouse antral follicle model offers experimental control and preserves important local follicular interactions, but it does not reproduce whole-animal absorption, distribution, metabolism, or endocrine feedback through the hypothalamic-pituitary-ovarian axis. It also cannot determine whether the observed responses would occur at comparable internal MEHP concentrations in humans.

The study used the MEHP metabolite rather than parent DEHP, which is appropriate for testing a biologically active ovarian exposure but limits conclusions about exposure scenarios in which metabolism controls tissue dose. The 96-hour culture design captures acute-to-subacute follicular responses, not long-term reproductive aging, ovulation, implantation, or fertility outcomes. In addition, CH223191-based rescue demonstrates that AhR signaling contributes to the phenotype, but it cannot by itself establish that AhR is the only relevant target or exclude all pharmacological off-target effects.

Future work should therefore test whether the pathway operates in vivo, determine how MEHP exposure changes AhR activity across ovarian cell types, and compare pharmacological findings with genetic loss-of-function approaches. Human granulosa-cell systems and clinically relevant exposure modeling would also be needed before translating the findings to human reproductive risk assessment. These next steps extend the paper’s conclusions without assuming that all AhR ligands produce identical ovarian effects.

Research Support Resources

Researchers can use CH 223191 (SKU A8609) to support similar AhR-antagonist workflows, including experiments that measure receptor-responsive transcripts, steroid hormones, and follicle phenotypes. The product information provides formulation and storage details; experimental concentration, vehicle controls, exposure duration, and pathway-specific validation should be selected with the reference study and the relevant biological model in mind.